Heron Therapeutics signs long-term HQ lease in Cary

Heron Therapeutics, Inc. entered into a new long-term office lease for its corporate headquarters with USEF HCG Fenton LLC.

Rhea-AI Filing Summary

Heron Therapeutics, Inc. entered into a new long-term office lease for its corporate headquarters with USEF HCG Fenton LLC. The lease covers approximately 16,837 rentable square feet at 25 Fenton Main Street in Cary, North Carolina, with an initial term of about 111 months.

Beginning on the term commencement date, the company will pay monthly base rent of $614,550.50 for the first 12-month period, with base rent increasing by a set percentage in each following 12-month period. Heron will also pay its proportionate share of operating costs, although base rent and estimated operating costs will be abated for a specified number of months after the commencement date. The lease includes a one-time option to extend for an additional 84 months and a one-time right of first refusal on contiguous vacant space.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Heron Therapeutics (HRTX) disclose in this 8-K filing?

Heron Therapeutics disclosed that it entered into a new Office Lease Agreement for its corporate headquarters with USEF HCG Fenton LLC, covering approximately 16,837 rentable square feet in Cary, North Carolina, with a long-term lease structure and options for extension and additional space.

Where will Heron Therapeutics’ new corporate headquarters be located?

The new corporate headquarters will be located at 25 Fenton Main Street, Cary, North Carolina, 27511, comprising approximately 16,837 rentable square feet in the building.

What is the initial term of the new Heron Therapeutics (HRTX) headquarters lease?

The initial term of the new headquarters lease is approximately 111 months, giving Heron Therapeutics a long-duration commitment for its corporate offices.

How much base rent will Heron Therapeutics pay under the new lease?

Starting on the term commencement date, Heron Therapeutics will pay a monthly base rent of $614,550.50 for the first 12-month term, with base rent increasing by a specified percentage in each subsequent 12-month term.

Does the Heron Therapeutics lease include options to extend or expand the space?

Yes. The lease grants Heron Therapeutics a one-time option to extend the term for an additional 84 months, and a one-time right of first refusal on contiguous vacant space that becomes available for lease, subject to the landlord’s offer terms.

Will any rent or operating costs be abated for Heron Therapeutics under this lease?

Yes. The agreement provides that base rent and estimated operating costs will be abated for a certain number of months after the term commencement date, in addition to ongoing obligations for base rent and a proportionate share of operating costs.

Where can investors find the full terms of the Heron Therapeutics lease?

The company stated that a copy of the full Office Lease Agreement will be filed as an exhibit to Heron Therapeutics’ Quarterly Report on Form 10-Q for the period ending September 30, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/28/2025 - 05:02 PM EDT Learn about SEC filing dates

0000818033false00008180332025-08-222025-08-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 22, 2025

Heron Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-33221		94-2875566
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

100 Regency Forest Drive, Suite 300, Cary, NC		27518
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (858) 251-4400

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		HRTX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry Into a Material Definitive Agreement.

Heron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Office Lease Agreement (the “Lease”), dated as of August 22, 2025, with USEF HCG Fenton LLC, a Delaware limited liability company (the “Landlord”). The Lease is for the Company’s new corporate headquarters, which is approximately 16,837 rentable square feet (the “Premises”) at 25 Fenton Main Street, Cary, North Carolina, 27511 (the “Building”).

The Lease provides for a term of approximately one hundred eleven months. Under the terms of the Lease, the Tenant has the option to extend the Lease one time for a period of eighty-four additional months, by providing written notice to the Landlord not more than 18 months nor less than 12 months prior to the expiration date. In addition, during the term of the Lease, the Lease also provides the Tenant with a one-time “right of first refusal” with respect to any vacant space contiguous to the Premises, when such space becomes available for lease, subject to any terms provided by the Landlord in connection with the offer to lease such space.

Beginning on the Commencement Date (the “Term Commencement Date”), the Company’s monthly base rent under the Lease will be $614,550.50 for the first 12-month term, which will increase by a certain percentage per each subsequent 12-month term, and will also be responsible for paying its proportionate share of operating costs; provided, that base rent and estimated operating costs will be abated during a certain number of months after the Term Commencement Date.

The Lease contains customary representations, warranties, and covenants.

The foregoing description of the Lease is not complete and is qualified in its entirety by reference to the complete terms and conditions of the Lease. A copy of the Lease will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ending September 30, 2025.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Exhibit
104		Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Heron Therapeutics, Inc.
Date: August 28, 2025			/s/ Ira Duarte
			Ira Duarte
			Executive Vice President, Chief Financial Officer